Socioeconomic status (SES) is a well-known determinant of outcomes in cancer. The purpose of this study was to analyze the impact of the SES on the outcomes of Hodgkin lymphoma (HL) patients from the Brazilian Prospective HL Registry. SES stratification was done using an individual asset/education-based household index. A total of 624 classical HL patients with diagnosis from January/2009 to December/2014, and treated with ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine), were analyzed. The median follow-up was 35.6 months, and 33% were classified as lower SES. The 3-year progression-free survival (PFS) in higher and lower SES were 78 and 64% (p < 0.0001), respectively. The 3-year overall survival (OS) in higher and lower SES were 94 and 82% (p < 0.0001), respectively. Lower SES patients were more likely to be 60 years (16 vs. 8%, p 5 0.003), and to present higher risk International Prognostic score (IPS) (44 vs. 31%, p 5 0.004) and advanced disease (71 vs. 58%, p 5 0.003). After adjustments for potential confounders, lower SES remained independently associated with poorer survival (HR 5 3.12 [1.86-5.22] for OS and HR 5 1.66 [1.19-2.32] for PFS). The fatality ratio during treatment was 7.5 and 1.3% for lower and higher SES (p 5 0.0001). Infections and treatment toxicity accounted for 81% of these deaths. SES is an independent factor associated with shorter survival in HL in Brazil. Potential underlying mechanisms associated with the impact of SES are delayed diagnosis and poorer education. Educational and socio-economic support interventions must be tested in this vulnerable population.
The outcome of Hodgkin's lymphoma (HL) has markedly improved over the past few decades, making HL one of the cancers with the greatest chances of cure. 1 However, data about HL in developing countries are limited and come mostly from retrospective series. [2] [3] [4] [5] [6] These data suggest the existence of substantial disparities in health care and treatment outcomes for HL patients in large areas of the world.
In 2009, the Brazilian Prospective Hodgkin Lymphoma Registry was implemented to gather data on socio-demographic features, clinical presentation, treatment modalities and outcomes. We have recently published the first report of patients included in the Brazilian Prospective Hodgkin Lymphoma Registry. 7 The main treatment outcomes were inferior to those observed in developed countries, even when stratified by risk groups. 7 Brazil is a country of extreme wealth inequality. While it ranks among the ten nations with larger Gross Domestic Products (GDP), 8 Brazil's GDP per capita ranks at 108, 9 and the family income inequality index (GINI index) is the 16th worse among 145 evaluated nations. 9 Therefore, it is imperative to take into account socioeconomic aspects when interpreting treatment results in Brazil.
Socioeconomic status (SES), a wide concept including both economic and social resources, is a strong predictor of morbidity and premature mortality worldwide, 10 and a wellknown determinant of outcomes in cancer. 11, 12 There is a growing body of evidence suggesting substantial disparities in cancer treatment outcomes determined by economic and social factors, even within developed nations. [13] [14] [15] [16] Inequalities in survival according to socioeconomic status in lymphoma patients have also been reported. 15, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The purpose of the present study was to analyze the impact of the SES on the outcomes of HL patients retrieved from the Brazilian Prospective Hodgkin Lymphoma Registry.
Methods

Patients and methods
The Brazilian Prospective Hodgkin's Lymphoma Registry (NCT02589548) is an observational prospective cohort study initiated in January 2009. At the moment of the present analysis, it has 20 participating institutions: 18/20 are public institutions, and 12/20 are university-affiliated hospitals. They are located in seven out of 26 states in Brazil; most centers are located in the South and Southeast regions, where most of the country's population lives. All public institutions treat patients within the Brazilian public health system, which provides free universal access. Institutional participation in the Registry is voluntary. Institutions joining the Registry agreed to invite every new HL patient to participate in the Registry. All centers have access to pathology facilities with standard morphological and immunohistochemical methods for the diagnosis of HL. The Registry includes full clinical information about each patient. All records are reviewed centrally and checked for data coherence and completeness. Members of the Registry's central board have visited centers when needed to ensure the quality of the data records. 7 The ethics committees of the participating institutions approved the study, and all patients signed an informed consent for the present study.
A total of 674 patients with a diagnosis of classical HL until December 31, 2014, age 13 years-old and human immunodeficiency virus (HIV) negative were initially identified. Among them, 624 patients treated with the chemotherapy combination ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) were included in the present analysis. 7 The remaining 50 patients, treated with different protocols, were not included to favor a more homogeneous study sample.
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Clinical and socio-demographic characteristics contrast to those with a PS of 2, who were defined as having poorer performance. All treatment decisions were made at the physicians' discretion, according to each institution's clinical practice.
Socioeconomic evaluation
Socioeconomic status stratification was performed using an asset/education-based household index called the "Criteria for Economic Classification," which has been widely used in publicity and political polls in Brazil. 31 Each patient answered a questionnaire with items that indicate the educational level of the household's head and the ownership of several household goods. It is a point system, with established weights for existing goods in the household. 31 According to the total number of points, patients are placed in a socioeconomic status category (A1, A2, B1, B2, C1, C2, D, E). For this study's analysis, the categories were merged in two groups: the higher SES group (categories A1 to C1) with an index > 17, and the lower SES group (categories C2, D and E), with up to 17 points in the index.
Educational level was categorized as illiterate to incomplete elementary school ( 4 years of schooling), complete elementary school (5 years of schooling), complete middle school (9 years of schooling), high school, and complete superior.
Outcome definitions
Responses were defined according to the 1999 international criteria. 32 Imaging evaluation was based on computed tomography (CT) scans only, because 18 F-fluorodeoxyglucosepositron emission tomography (PET)/CT scans remain unavailable for most patients in Brazil. Progression was defined as relapse or failure to achieve complete remission or unconfirmed complete remission. Overall survival (OS) was the time measured in months from the date of diagnosis to the date of death or last contact. Progression-free survival (PFS) was the time measured in months from the date of diagnosis until the date of progression or death or last contact. All patients were included at the moment of diagnosis. Date of diagnosis was the start of follow-up. Patients were followed until death or last contact. Date of last contact was the censoring date. The date of last follow-up was August 31, 2016.
The "fatality ratio during treatment" was defined as the proportion of patients who died of any cause during frontline treatment for HL, or in the 30 days subsequent to frontline treatment completion.
Statistical analysis
Standard descriptive analyzes were performed. For a crude association analysis, categorical data were studied using v 2 or Fisher's exact test (two-sided), whereas the Mann-Whitney test was used for continuous data. Survival curves were estimated using the Kaplan-Meier method and compared with the logrank test. The impact of SES was evaluated regarding two outcome measures: OS and PFS. Cox regression analyses were conducted to evaluate the possible impact of SES on OS and PFS, controlled for a set of covariates which are wellestablished prognostic factors, and could potentially be also associated with SES. Hence, we aimed to estimate the hazard ratio (HR) of death or progression according to SES categories, adjusted for these covariates. We knew from a previous analysis 17 that lower SES patients might often present a high IPS risk and advanced disease. Thus, the covariates included in the model were relevant patients' characteristics, such as age (< 60 or 60 or more) and performance status (ECOG scale 0-1 or 2), prognostic factors such as the IPS (low-risk or highrisk) and the GHSG classification for stage risk categories (nonadvanced or advanced). The time elapsed from the beginning of symptoms to diagnosis ( 4 or > 4 months) was included as a proxy for ease of access to health care, and histopathology (nodular sclerosis or non-nodular sclerosis), was included as a biological characteristic of the disease. Traditional cut points were used for the categorization of these covariates. A multiple Cox proportional hazards model was fitted to estimate the HR of death or progression according to SES categories, adjusted for the covariates mentioned above.
Interaction between SES and age (< 60 or 60 years old) was tested by including the interaction term in the multivariate model. The reason to evaluate the effect of age was the well-known presentation with advanced disease and a poor risk profile, and also the inferior outcomes seen in older HL patients, which have been attributed to a variety of factors including comorbidities, biology (higher prevalence of the mixed cellularity subtype) and increased treatment-related toxicity. 33 In all models, the proportional hazards assumption was tested based on inspection of the survival curves [log (-Log) of the survival distribution function by log (months)]. The results of the multivariate analyses were presented as HR of death or progression according to SES categories, with respective 95% confidence intervals (CI). The SPSS software (Chicago, IL) was used for data analysis.
Results
A total of 624 classical HL patients were available for the present analysis. Patients' characteristics at diagnosis are shown in Table 1 . Their median age was 30 years-old (13-90) and 318 (51%) patients were women. Detailed characteristics of the patients in the Registry have been recently published. 7 Comparison of clinical characteristics between higher and lower SES Socio-economic status information was available in 93% of the patients (578/624). Lower SES patients were more likely to have age 60 years (16 vs. 8%, p 5 0.003), to have a poorer performance status (20 vs. 10%, p 5 0.001), a higher risk IPS (44 vs. 31%, p 5 0.004), to present with advanced disease (71 vs. 58%, p 5 0.003) and to have a histopathological diagnosis other than nodular sclerosis (31 vs. 19%, p 5 0.002). Also, time to diagnosis > 4 months was more frequent in lower SES patients (69 vs. 53%, p 5 0.0001; Table 1 ).
The median time elapsed from the beginning of symptoms until diagnosis for higher and lower SES was 5 months and 7 months, respectively (p 5 0.001), and 6 months and 7.5 months for patients with 5 years of schooling or 4 years of schooling, respectively (p 5 0.08).
Adherence to the ABVD treatment protocol was good, irrespective of SES: the median duration of each cycle of ABVD for higher and lower SES was 28 days and 28.5 days, respectively, while the total duration of treatment for patients with advanced disease with higher and lower SES was 6.17 and 6.22 months, respectively.
Overall and progression-free survival analysis
The median follow-up was 35.6 months for all patients and 39.6 months for patients alive at the time of analysis. The 3-y PFS in higher and lower SES was 78 and 64% (p < 0.0001), respectively (Fig. 1a) . The 3-year OS in higher and lower SES was 94 and 82% (p < 0.0001), respectively (Fig. 1b) .
After adjustments for potential confounders (age, PS, advanced disease, IPS, histopathology and time to diagnosis), lower SES remained independently associated with poorer OS (HR 5 3.12, 95% CI 1.86-5.22, p < 0.0001), and with poorer PFS (HR 5 1.66, 95% CI 1.19-2.32, p 5 0.003). Also, a stratified Cox proportional hazards analysis was performed to estimate the adjusted HR according to SES categories for younger and older patients, since the multiplicative interaction between age and SES was statistically significant (p 5 0.02 for OS, p 5 0.004 for PFS). The results of the Cox analyses for OS and PFS are presented in Tables 2 and 3 .
Deaths during first treatment
Twenty-one (3.1%) patients died during front-line treatment. In 17 (81%) of these patients, the cause of death was an infection or a complication of treatment (three deaths due to lung toxicity and one due to cardiotoxicity). The remaining patients died due to disease progression in two patients, gastrointestinal bleeding in one patient, and unknown cause in one patient. Also, one patient died of cardiac failure (attributed to cardiologic toxicity) 5 months after the end of treatment, and it was not possible to assess his treatment outcomes.
A higher fatality ratio during treatment was observed among lower SES patients compared to higher SES patients (7.5 vs 1.3%, p < 0.0001). Also, a higher fatality ratio during treatment was observed among patients with 4 years of schooling, when compared to those with 5 years of schooling (17.6 vs 2.6%, p 5 0.001).However, no differences in fatality ratios during treatment were found regarding some socio-demographic aspects: it was 3% (7/222) and 4% (10/250, p 5 0.8) for patients residing closest to the hospital (up to 40 km) or not (> 40 km), and it was 3.5% (13/372) and 3% (3/101, p 5 1.0) for patients who spent up to 3 hrs to arrive at the hospital or more, respectively. Also, the fatality ratios during treatment of patients who had or did not have someone to help bring them to the hospital in an urgency were 4% (17/438) and 3% (4/135, p 5 0.8), respectively.
Discussion
In the present prospective cohort study of Brazilian patients with HL, we sought to investigate the impact of SES, measured by an asset/education-based individual household index, on the treatment outcomes of HL. Lower SES patients were more likely to present with advanced disease and poor prognostic features, and had a shorter PFS and OS. After adjustments for potential confounders -such as age, PS, poor prognostic features (advanced stages and IPS), histopathologic subtype, and time to diagnosis -SES remained independently associated with a shorter survival. The impact of SES on survival was higher in patients aged 60 years or older. A higher than expected fatality ratio during treatment was observed, mainly among lower SES patients (7.5%). This finding is in accordance with those of a previous cohort of Brazilian HL patients. 17 In contrast, the fatality ratio during ABVD treatment varied from 0 to 0.3% in three recent studies in developed countries. [34] [35] [36] The early mortality seen in our patients was due mainly to infections and toxicity. No differences in SES were found according to the distance and travel time from residence to the hospital, or to the availability of someone to transport the patient to the hospital if necessary. A large number of studies have documented the impact of SES inequalities in cancer survival, 11, 12 even in highly developed countries such as Sweden and Switzerland. 14, 16 The underlying mechanisms associated with this so-called deprivation gap in cancer survival are a subject of debate, with potential mediators related to the patients' educational level, delayed diagnosis, adherence to treatment, comorbidities, and biology of the disease. There are often interconnections among these mediators. 11, 12 A few studies about the impact of SES on HL outcomes have been performed. 15, [17] [18] [19] [20] [21] [23] [24] [25] [26] [27] 37, 38 Different strategies for SES stratification have been used in these studies, including the neighborhood SES, racial/ethnic differences, the medical insurance status and specific local measures, such as the Ontario Marginalization Index. Disparities in survival according to SES were observed in almost all of these studies, except for those in Canada and Denmark, in which patients are treated in universal health care systems. 37, 38 Although our patients were also treated within Brazil's universal health care system, SES disparities are probably much more marked, and could not be overcome by treatment in good quality medical centers. Although the present study was not planned to explore the underlying mechanisms associated with the impact of SES on treatment outcomes, data available from our patients allow a few considerations. One plausible mechanism is delayed diagnosis. The time elapsed from the beginning of symptoms to diagnosis was longer in lower SES patients. This delay could be due to difficulties in accessing the primary health system, in the primary physician's ability to raise the hypothesis of lymphoma, in the health system's capacity to timely process image and biopsy procedures, and also to a delay in the patient's initiative to look for healthcare services due to a lack of awareness of the potentially grave meaning of the initial clinical symptoms. There is a close relationship between delay in diagnosis and stage of the disease at diagnosis. 11, 12, 39, 40 Many studies in lymphoma have shown that lower SES patients present more often in advanced stages. [18] [19] [20] [21] 23, 41 In the present study, lower SES patients were not only more likely to present in advanced stages, but they also had a poor-risk prognostic profile. However, in almost all studies in lymphoma that showed an association between SES and extension of the disease, including the present one, the differences in outcomes are not entirely explained by the extension of the disease when multivariate analyses were performed with adjustment by stage and other prognostic risk factors. 18, 19, 21, 23, 41 In other words, while the SES has a close association with stage at diagnosis, its effect on treatment outcomes transcends this association. Many authors have reported the effect of a low educational level on mortality and survival in lymphoma and other diseases, even when controlling for stage. 14, 23 In two studies from Sweden, individuals with a graduate degree had cancer survival rates 40% higher than those with less than nine years of school attendance. 42, 43 A low educational level might undermine the patient's initiative to seek healthcare services, leading to a delay in diagnosis of the primary disease or a life-threatening complication. 12 Indeed, in our patients, the median time from the onset of symptoms to diagnosis was longer in patients with fewer years of schooling, and a higher number of fatal events occurred in patients with a low educational level.
Adherence to treatment is a well-recognized reason for disparities in outcomes in many diseases. 44 However, it is an unlikely factor in the present study. ABVD is an entirely intravenous regimen administered in outpatient clinics. A few available time measures, namely the median duration of each cycle and the median total duration of treatment, strongly suggest that ABVD was properly administered and did not differ between SES groups.
A different biology of the disease could have a role in the shorter survival observed in lower SES patients. Although this possibility cannot be discarded, a few factors speak against it. The increased fatality ratio observed during treatment in lower SES patients was mostly due to infections and other treatment toxicities, which are unlikely related to biologic characteristics of the lymphoma. One aspect of the biology of HL that has been related to socioeconomic factors is the prevalence of the mixed cellularity histopathologic subtype of HL. [45] [46] [47] Patients in underdeveloped countries, as well as those in rural areas in developed countries, had a higher prevalence of mixed cellularity. This difference disappeared with industrialization and urbanization. 46, 47 The reasons for this transition remain elusive, but authors have speculated about early Epstein-Barr virus contact and the effectiveness of the immune system in disadvantaged patients. 46 In Brazil, we have seen a similar transition, from a high prevalence (35%-40%) of cases of mixed cellularity before the 1990s, 3 to the current 20%. In a previous study, 17 there were no differences in the prevalence of mixed cellularity between higher and lower SES patients. In the present study, there were 7% more patients with the mixed cellularity subtype among lower SES patients, but this might be an effect of the higher prevalence of patients older than 60 among lower SES patients, since elderly HL patients also present more frequently with the mixed cellularity subtype. 33 Moreover, histopathology was included in the multivariate analysis in the present study, and the observed SES effect is controlled for this variable.
Since the improvement of socio-economic conditions is a long-term endeavor, specific preventive measures should be tested in socially and clinically vulnerable HL patients. Measures that could possibly favor these patients include a fast track access to a multidisciplinary health care team; repeated instructions to patients and relatives regarding the symptoms and signs that might indicate infection, toxicity or disease activity; and a more liberal use of growth factors than currently advised for ABVD treatment. Patients with a low SES, and particularly those with a low education level, might also benefit from having a family member or close friend designated as a primary caregiver during treatment. Moreover, a conditional cash transfer program for patients in treatment could be tested. 48 Ultimately, the deprivation gap in HL survival will only be overcome by better education, social inclusion, and improvements in the national public health system.
